Treatment details and follow-up data of included patients
| Patient . | Cumulative dose of sutimlimab in the extension trial [g] . | Duration of participation in the extension trial [mo] . | Cumulative exposure to sutimlimab (NPP + extension trial) [mo] . | Monospecific Coombs test (DAT) at sutimlimab discontinuation . | Cold agglutinin titer at sutimlimab discontinuation . | Monospecific Coombs test (DAT) at 12 mo . | Sustained hematologic remission . |
|---|---|---|---|---|---|---|---|
| 1 | 519.5 | 38 | 58 | Anti-IgG – Anti-IgM – Anti-C3d – | 256 | Anti-IgG - Anti-IgM - Anti-C3d +++ | yes |
| 2 | 475.0 | 34 | 39.5 | Anti-IgG – Anti-IgM – Anti-C3d + | 256 | Anti-IgG - Anti-IgM - Anti-C3d ++ | yes |
| 3 | 503.5 | 39 | 59 | Anti-IgG –∗ Anti-IgM ++ Anti-C3d ++ | >1024 | Anti-IgG + Anti-IgM +++ Anti-C3d ++ | no |
| Patient . | Cumulative dose of sutimlimab in the extension trial [g] . | Duration of participation in the extension trial [mo] . | Cumulative exposure to sutimlimab (NPP + extension trial) [mo] . | Monospecific Coombs test (DAT) at sutimlimab discontinuation . | Cold agglutinin titer at sutimlimab discontinuation . | Monospecific Coombs test (DAT) at 12 mo . | Sustained hematologic remission . |
|---|---|---|---|---|---|---|---|
| 1 | 519.5 | 38 | 58 | Anti-IgG – Anti-IgM – Anti-C3d – | 256 | Anti-IgG - Anti-IgM - Anti-C3d +++ | yes |
| 2 | 475.0 | 34 | 39.5 | Anti-IgG – Anti-IgM – Anti-C3d + | 256 | Anti-IgG - Anti-IgM - Anti-C3d ++ | yes |
| 3 | 503.5 | 39 | 59 | Anti-IgG –∗ Anti-IgM ++ Anti-C3d ++ | >1024 | Anti-IgG + Anti-IgM +++ Anti-C3d ++ | no |
Results of the monospecific Coombs test before treatment have been reported previously.12
Cumulative doses of sutimlimab in the NPP are shown in the appendix.
Patient 3 intermittently tested positive for IgG autoantibodies, compatible with mixed AIHA.